167 related articles for article (PubMed ID: 35248829)
1. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.
Silic-Benussi M; Sharova E; Ciccarese F; Cavallari I; Raimondi V; Urso L; Corradin A; Kotler H; Scattolin G; Buldini B; Francescato S; Basso G; Minuzzo SA; Indraccolo S; D'Agostino DM; Ciminale V
Redox Biol; 2022 May; 51():102268. PubMed ID: 35248829
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus.
Silic-Benussi M; Sharova E; Corradin A; Urso L; Raimondi V; Cavallari I; Buldini B; Francescato S; Minuzzo SA; D'Agostino DM; Ciminale V
Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978873
[TBL] [Abstract][Full Text] [Related]
3. Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis.
Silic-Benussi M; Scattolin G; Cavallari I; Minuzzo S; Del Bianco P; Francescato S; Basso G; Indraccolo S; D'Agostino DM; Ciminale V
Cell Death Dis; 2018 Aug; 9(8):822. PubMed ID: 30069011
[TBL] [Abstract][Full Text] [Related]
4. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism.
Dando I; Pacchiana R; Pozza ED; Cataldo I; Bruno S; Conti P; Cordani M; Grimaldi A; Butera G; Caraglia M; Scarpa A; Palmieri M; Donadelli M
Free Radic Biol Med; 2017 Dec; 113():176-189. PubMed ID: 28962872
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
6. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Carroll WL; Aifantis I; Raetz E
Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
[TBL] [Abstract][Full Text] [Related]
7. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
[TBL] [Abstract][Full Text] [Related]
8. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
9. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
[TBL] [Abstract][Full Text] [Related]
11. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
[TBL] [Abstract][Full Text] [Related]
12. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.
Zhang C; Ryu YK; Chen TZ; Hall CP; Webster DR; Kang MH
Leuk Res; 2012 Mar; 36(3):342-9. PubMed ID: 22137317
[TBL] [Abstract][Full Text] [Related]
14. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
[TBL] [Abstract][Full Text] [Related]
15. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
[No Abstract] [Full Text] [Related]
17. mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.
Baraz R; Cisterne A; Saunders PO; Hewson J; Thien M; Weiss J; Basnett J; Bradstock KF; Bendall LJ
PLoS One; 2014; 9(7):e102494. PubMed ID: 25014496
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
Wong J; Welschinger R; Hewson J; Bradstock KF; Bendall LJ
Oncotarget; 2014 Nov; 5(21):10460-72. PubMed ID: 25361005
[TBL] [Abstract][Full Text] [Related]
19. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
